New treatments for type 2 diabetes--the DPP4 inhibitors.
Sitagliptin (brand name Januvia) the first of a new class of oral agents, the DPP4 inhibitors, which lower blood glucose in type 2 diabetes has recently been launched in UK. Another DPP4 inhibitor vildagliptin is due to be launched soon, and there are several others in the pipeline. This article gives an overview of this new class of medications.
Gadsby
Roger
R
Warwick Medical school, University of Warwick, Institute of Education, Gibbet Hill Road Coventry, Warwickshire CV4 7AL, United Kingdom. rgadsby@doctors.org.uk
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D000077597:Vildagliptin
D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate